<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Butterman, Eric</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bucaneve, Giampaolo</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tigecycline plus Standard Therapy is More Effective than Standard Therapy Alone for Treating Infections in Febrile Neutropenic Cancer Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Tigecycline, first in a new class of glycylcyclines, in combination with piperacillin/tazobactam, is effective, safe, and well tolerated in high-risk febrile neutropenic oncohematologic patients. This combination therapy may aid in reducing the increase and extensive use of carbapenems, which have been associated with an increase in multidrug-resistant bacteria.</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>